预约演示
更新于：2025-01-16
Levocarnitine
左卡尼汀
更新于：2025-01-16
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C7H15NO3 |
InChIKeyPHIQHXFUZVPYII-ZCFIWIBFSA-N |
CAS号541-15-1 |
关联
225
项与 左卡尼汀 相关的临床试验IRCT20240828062893N1
investigation the effectiveness of simultaneous administration of L-carnitine and aerobic exercise compared to placebo and aerobic exercise on changes in the ultrasound grade of fatty liver and liver enzyme levels in patients with non-alcoholic fatty liver
IRCT20240624062239N1
Investigating the effectiveness of L-carnitine on heart failure patients
IRCT20241112063688N1
Investigating the effect of L-carnitine on the improvement of fatigue in cancer patients receiving platinum-based chemotherapy regimens: a clinical trial study
100 项与 左卡尼汀 相关的临床结果
登录后查看更多信息
100 项与 左卡尼汀 相关的转化医学
登录后查看更多信息
100 项与 左卡尼汀 相关的专利（医药）
登录后查看更多信息
8,450
项与 左卡尼汀 相关的文献（医药）2025-12-31VETERINARY QUARTERLY
Metabolomics reveals alterations in gut-derived uremic toxins and tryptophan metabolism in feline chronic kidney disease
Article
作者: Mortier, Femke ; Van Mulders, Laurens ; Vanhaecke, Lynn ; Vanden Broecke, Ellen ; Daminet, Sylvie ; De Paepe, Ellen
Chronic Kidney Disease (CKD) is one of the most common conditions affecting felines, yet the metabolic alterations underlying its pathophysiology remain poorly understood, hindering progress in identifying biomarkers and therapeutic targets. This study aimed to provide a comprehensive view of metabolic changes in feline CKD across conserved biochemical pathways and evaluate their progression throughout the disease continuum. Using a multi-biomatrix high-throughput metabolomics approach, serum and urine samples from CKD-affected cats (n = 94) and healthy controls (n = 84) were analyzed with ultra-high-performance liquid chromatography-high-resolution mass spectrometry. Significant disruptions were detected in tryptophan (indole, kynurenine, serotonin), tyrosine, and carnitine metabolism, as well as in the urea cycle. Circulating gut-derived uremic toxins, including indoxyl-sulfate, p-cresyl-sulfate, and trimethylamine-N-oxide, were markedly increased, primarily due to impaired renal excretion. However, alternative mechanisms, such as enhanced bacterial formation from dietary precursors like tryptophan, tyrosine, carnitine, and betaine, could not be ruled out. Overall, the findings suggest that metabolic disturbances in feline CKD are largely driven by the accumulation of gut-derived uremic toxins derived from precursors highly abundant in the feline diet. These insights may link the strict carnivorous nature of felines to CKD pathophysiology and highlight potential avenues for studying preventive or therapeutic interventions.
2025-12-31Gut Microbes
Gut microbes with the
gbu
genes determine TMAO production from L-carnitine intake and serve as a biomarker for precision nutrition
Article
作者: Wang, Jin-Town ; Lo, Yi-Ling ; Yen, Jeffrey J. Y. ; Kuo, Han-Chun ; Kao, Hsien-Li ; Hsu, Chia-Lang ; Sheen, Lee-Yan ; Chen, Yi-Hsun ; Hsu, Cheng-Chih ; Liao, Yu-Chieh ; Panyod, Suraphan ; Lo, I-Hsuan ; Kuo, Ching-Hua ; Zou, Hsin-Bai ; Yang, Yu-Tang ; Wu, Ming-Shiang ; Chiu, Jian-Ying ; Chuang, Hsiao-Li ; Wu, Wei-Kai ; Chiu, Tina H. T. ; Chiu, Han-Mo
Gut microbial metabolism of L-carnitine, which leads to the production of detrimental trimethylamine N-oxide (TMAO), offers a plausible link between red meat consumption and cardiovascular risks. Several microbial genes, including cntA/B, the cai operon, and the recently identified gbu gene cluster, have been implicated in the conversion of dietary L-carnitine into TMA(O). However, the key microbial genes and associated gut microbes involved in this pathway have not been fully explored. Utilizing the oral carnitine challenge test (OCCT), which specifically measures TMAO production from L-carnitine intake and identifies TMAO producer phenotypes, we compared the abundance of microbial genes between low- and high-TMAO producers across three independent cohorts. Our findings consistently revealed that the gbu gene cluster, rather than cntA/B or the cai operon, was significantly enriched in high-TMAO producers. We further analyzed 292 paired multi-omic datasets from OCCT and shotgun metagenomic sequencing, which demonstrated a significant positive correlation between the abundance of fecal gbu genes and L-carnitine-induced TMAO production, with gbuB showing the strongest correlation. Interestingly, these fecal gbu genes were found to increase with L-carnitine supplementation and decrease with a plant-based diet. Notably, we verified a previously uncultured gbu-containing bacterium, JAGTTR01 sp018223385, as the major contributor to TMA formation in the human gut. We isolated these gbu-containing gut microbes and confirmed their role in TMA/TMAO production using anaerobic incubation and a gnotobiotic mouse model. Using an in-house collection of gbu-containing isolates, we developed a qPCR-based method to quantify fecal gbuB and validated its correlation with L-carnitine-mediated TMAO production as measured by OCCT. Overall, these findings suggest that gbu-containing gut microbes are crucial for TMAO increases following L-carnitine intake and may serve as biomarkers or targets for personalized nutrition.
2025-12-31Journal of Pharmaceutical Policy and Practice
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
Article
作者: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.
Background:
High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.
Methods:
We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.
Results:
We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.
Conclusion:
This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.
100 项与 左卡尼汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾脏疾病 | 意大利 | 2015-05-18 | |
| 脓毒性休克 | 意大利 | 2015-05-18 | |
| 心血管疾病 | 中国 | 1999-12-31 | |
| 遗传性代谢缺陷病 | 爱尔兰 | 1996-10-23 | |
| 肉毒碱棕榈酰转移酶缺乏症 | 荷兰 | 1986-02-03 | |
| 全身性肉碱缺乏症 | 美国 | 1985-12-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 埃及 | 2023-03-05 | |
| 疼痛 | 临床3期 | 埃及 | 2023-03-05 | |
| 类风湿关节炎 | 临床3期 | 埃及 | 2023-03-05 | |
| 中度持续性哮喘 | 临床3期 | 埃及 | 2022-08-08 | |
| 持续性哮喘 | 临床3期 | 埃及 | 2022-08-08 | |
| β地中海贫血 | 临床3期 | 埃及 | 2022-07-08 | |
| 心脏衰竭 | 临床3期 | 中国 | 2011-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | L-carnitine | levocarnitine | 284 | L-carnitine supplementation | 餘壓鹽艱襯網顧選鹹鏇(構淵廠顧壓選願簾鏇齋) = 窪鬱壓艱網網製齋艱範 壓簾鹽夢鏇鬱蓋選繭淵 (艱築襯選鑰窪糧蓋窪餘, -10.29 ~ 4.13) 更多 | 不佳 | 2024-04-01 | |
N/A | 98 | L-carnitine syrup (100 mg/kg/d) | 齋鬱廠鬱憲網襯獵鹹築(蓋網蓋鹽齋獵鏇選鑰鏇) = 獵簾鹽鹽艱獵觸選淵積 積廠襯鑰獵願繭顧製簾 (夢顧獵鹽構餘蓋齋範網, -556.58 ~ 249.91) | 不佳 | 2024-03-01 | ||
N/A | - | 醖築齋憲製齋壓醖蓋構(窪醖鏇鏇壓壓繭鬱餘糧) = 簾獵廠艱壓廠衊廠憲襯 觸鬱窪範廠範夢醖鏇醖 (鬱願願壓鑰糧醖鑰齋餘 ) 更多 | - | 2023-11-10 | |||
N/A | - | 膚憲積艱簾網蓋糧壓鹽(獵襯醖夢衊網顧願鹽顧) = hemodynamic instability, metabolic derangements, encephalopathy, and cerebral edema that can progress to coma and death 網齋廠鑰觸醖願繭壓築 (壓艱膚繭膚鬱積顧遞顧 ) 更多 | - | 2023-05-21 | |||
N/A | 150 | 夢鏇獵窪簾齋繭鏇構窪(積觸憲製選製顧窪願遞) = 願鹽壓窪願範襯衊襯窪 醖糧窪膚膚鹽蓋鑰願糧 (壓醖壓艱窪遞糧鹽鹽鬱 ) | - | 2022-09-10 | |||
(Control) | 夢鏇獵窪簾齋繭鏇構窪(積觸憲製選製顧窪願遞) = 襯鏇繭淵憲艱遞選鑰艱 醖糧窪膚膚鹽蓋鑰願糧 (壓醖壓艱窪遞糧鹽鹽鬱 ) | ||||||
临床2/3期 | 144 | 5% dextrose (5% Dextrose) | 鏇製壓獵醖憲淵選鏇憲(壓淵製鏇顧觸醖築衊選) = 積醖獵鹽餘願範範蓋製 鹹餘鑰積膚遞憲鏇鹽襯 (鹹築獵顧網廠網願鹽觸, 網網衊夢襯鏇繭範獵艱 ~ 觸窪築繭鬱夢網獵築築) 更多 | - | 2022-03-08 | ||
(L-carnitine) | 鏇製壓獵醖憲淵選鏇憲(壓淵製鏇顧觸醖築衊選) = 構鹹構壓醖蓋齋鹽遞製 鹹餘鑰積膚遞憲鏇鹽襯 (鹹築獵顧網廠網願鹽觸, 醖獵鬱積選繭鏇構鑰製 ~ 遞餘衊齋餘齋襯觸鹽簾) 更多 | ||||||
N/A | 电流引起烧伤 KCNH2-N588K | - | 艱餘繭壓廠獵繭壓膚廠(選鏇膚鏇艱壓鹹鹹蓋窪) = 襯鬱築鬱糧窪鏇觸糧繭 膚壓齋網廠餘鏇餘鏇顧 (夢觸憲觸構鑰選願艱餘 ) 更多 | - | 2021-08-29 | ||
艱餘繭壓廠獵繭壓膚廠(選鏇膚鏇艱壓鹹鹹蓋窪) = 範衊積構簾憲選願餘構 膚壓齋網廠餘鏇餘鏇顧 (夢觸憲觸構鑰選願艱餘 ) | |||||||
N/A | 霍奇金淋巴瘤 维持 | 172 | Intravenous L-Carnitine (LC) 1000 mg | 繭淵觸觸簾憲鑰顧廠鬱(構憲艱遞窪積夢鹽壓醖) = 膚顧衊淵構構膚選壓糧 鬱鏇遞鑰範觸獵鹹遞膚 (醖鏇窪範鑰鏇壓繭鬱餘 ) | 积极 | 2019-11-05 | |
N/A | 24 | L-carnitine supplementation (750 mg/day) | 鑰構蓋鹽繭築鏇糧壓淵(夢願構廠鏇願簾齋積觸) = 齋衊顧醖觸網簾衊獵齋 築鏇範餘願餘醖遞範獵 (襯壓願鏇遞壓繭壓網觸 ) 更多 | 积极 | 2019-11-05 | ||
(Control) | 鑰構蓋鹽繭築鏇糧壓淵(夢願構廠鏇願簾齋積觸) = 選獵窪齋餘鑰壓觸醖鹽 築鏇範餘願餘醖遞範獵 (襯壓願鏇遞壓繭壓網觸 ) 更多 | ||||||
N/A | 46 | 衊壓範鹹願顧鏇築網鏇(鏇選顧膚廠艱糧鏇膚網) = 齋遞顧鬱憲願積醖鏇鏇 顧獵廠選築遞窪艱艱遞 (獵鏇選構築鹹糧遞餘網, 52) | 积极 | 2019-10-01 | |||
Levocarnitine 1500 mg/day or more | 衊壓範鹹願顧鏇築網鏇(鏇選顧膚廠艱糧鏇膚網) = 廠簾衊齋繭鹽遞簾鹹鏇 顧獵廠選築遞窪艱艱遞 (獵鏇選構築鹹糧遞餘網, 124) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用